[1]
|
Eslam, M., Newsome, P.N., Sarin, S.K., et al. (2020) A New Definition for Metabolic Dysfunction-Associated Fatty Liver Disease: An International Expert Consensus Statement. Journal of Hepatology, 73, 202-209.
https://doi.org/10.1016/j.jhep.2020.07.045
|
[2]
|
Kuchay, M.S., Choudhary, N.S., Gagneja, S., et al. (2021) Low Skeletal Muscle Mass Is Associated with Liver Fibrosis in Individuals with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. Journal of Gastroenterology and Hepatology, 36, 3204-3211. https://doi.org/10.1111/jgh.15595
|
[3]
|
Dhanasekaran, R. and Felsher, D.W. (2019) A Tale of Two Complications of Obesity: NASH and Hepatocellular Carcinoma. Hepatology, 70, 1056-1058. https://doi.org/10.1002/hep.30649
|
[4]
|
Doycheva, I., Issa, D., Watt, K.D., Lopez, R., Rifai, G. and Alkhouri, N. (2018) Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in Young Adults in the United States. Journal of Clinical Gastroenterology, 52, 339-346. https://doi.org/10.1097/MCG.0000000000000925
|
[5]
|
Younossi, Z.M., Stepanova, M., Ong, J., et al. (2021) Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States. Clinical Gastroenterology and Hepatology, 19, 580-589.e5.
https://doi.org/10.1016/j.cgh.2020.05.064
|
[6]
|
Tsan, M.F. and Gao, B. (2004) Endogenous Ligands of Toll-Like Receptors. Journal of Leukocyte Biology, 76, 514-519.
https://doi.org/10.1189/jlb.0304127
|
[7]
|
Walton, K.A., Cole, A.L., Yeh, M., et al. (2003) Specific Phospholipid Oxidation Products Inhibit Ligand Activation of Toll-Like Receptors 4 and 2. Arteriosclerosis, Thrombosis, and Vascu-lar Biology, 23, 1197-1203.
https://doi.org/10.1161/01.ATV.0000079340.80744.B8
|
[8]
|
Walton, K.A., Hsieh, X., Gharavi, N., et al. (2003) Receptors Involved in the Oxidized 1-Palmitoyl-2-arachidonoyl- sn-glycero-3-phosphorylcholine-Mediated Synthesis of Interleukin-8. A Role for Toll-Like Receptor 4 and a Glycosylphosphatidylinositol-Anchored Protein. Journal of Biolog-ical Chemistry, 278, 29661-29666.
https://doi.org/10.1074/jbc.M300738200
|
[9]
|
Bäckhed, F., Ding, H., Wang, T., et al. (2004) The Gut Microbiota as an Environmental Factor That Regulates Fat Storage. Proceedings of the National Academy of Sciences of the United States of America, 101, 15718-15723.
https://doi.org/10.1073/pnas.0407076101
|
[10]
|
Betanzos-Cabrera, G., Estrada-Luna, D., Belefant-Miller, H. and Cancino-Díaz, J.C. (2012) Mice Fed with a High Fat Diet Show a Decrease in the Expression of Toll Like Receptor (TLR)2 and TLR6 mRNAs in Adipose and Hepatic Tissues. Nutrición Hospitalaria, 27, 1196-1203.
|
[11]
|
Kanuri, G., Ladurner, R., Skibovskaya, J., et al. (2015) Expression of Toll-Like Receptors 1-5 but Not TLR 6-10 Is Elevated in Liv-ers of Patients with Non-Alcoholic Fatty Liver Disease. Liver International, 35, 562-568.
https://doi.org/10.1111/liv.12442
|
[12]
|
Castrillo, A., Joseph, S.B., Vaidya, S.A., et al. (2003) Crosstalk between LXR and Toll-Like Receptor Signaling Mediates Bacterial and Viral Antagonism of Cholesterol Metabolism. Molecular Cell, 12, 805-816.
https://doi.org/10.1016/S1097-2765(03)00384-8
|
[13]
|
Ratziu, V., Harrison, S.A., Francque, S., et al. (2016) Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis without Fibrosis Worsening. Gastroenterology, 150, 1147-1159.e5. https://doi.org/10.1053/j.gastro.2016.01.038
|
[14]
|
Mouries, J., Brescia, P., Silvestri, A., et al. (2019) Microbio-ta-Driven Gut Vascular Barrier Disruption Is a Prerequisite for Non-Alcoholic Steatohepatitis Development. Journal of Hepatology, 71, 1216-1228.
https://doi.org/10.1016/j.jhep.2019.08.005
|
[15]
|
Shi, W., Wang, X., Tangchitpiyanond, K., Wong, J., Shi, Y. and Lusis, A.J. (2002) Atherosclerosis in C3H/HeJ Mice Reconstituted with Apolipoprotein E-Null Bone Marrow. Arterio-sclerosis, Thrombosis, and Vascular Biology, 22, 650- 655. https://doi.org/10.1161/01.ATV.0000013388.03553.31
|
[16]
|
Singh, A., Boden, G. and Rao, A.K. (2015) Tissue Factor and Toll-Like Receptor (TLR)4 in Hyperglycaemia-Hyper- insulinaemia. Effects in Healthy Subjects, and Type 1 and Type 2 Diabetes Mellitus. Thrombosis and Haemostasis, 113, 750-758. https://doi.org/10.1160/TH14-10-0884
|
[17]
|
Martínez-Montoro, J.I., Kuchay, M.S., Balaguer-Román, A., et al. (2022) Gut Microbiota and Related Metabolites in the Pathogenesis of Nonalcoholic Steatohepatitis and Its Resolution after Bariatric Surgery. Obesity Reviews, 23, e13367.
https://doi.org/10.1111/obr.13367
|
[18]
|
Del Chierico, F., Nobili, V., Vernocchi, P., et al. (2017) Gut Microbiota Profiling of Pediatric Nonalcoholic Fatty Liver Disease and Obese Patients Unveiled by an Integrated Meta-Omics-Based Approach. Hepatology, 65, 451-464.
https://doi.org/10.1002/hep.28572
|
[19]
|
Yamamoto, M. and Takeda, K. (2010) Current Views of Toll-Like Receptor Signaling Pathways. Gastroenterology Research and Practice, 2010, Article ID: 240365. https://doi.org/10.1155/2010/240365
|
[20]
|
Ye, D., Li, F.Y., Lam, K.S., et al. (2012) Toll-Like Receptor-4 Mediates Obesity-Induced Non-Alcoholic Steatohepatitis through Activation of X-Box Binding Protein-1 in Mice. Gut, 61, 1058-1067.
https://doi.org/10.1136/gutjnl-2011-300269
|
[21]
|
Zhang, R.N., Pan, Q., Zhang, Z., Cao, H.X., Shen, F. and Fan, J.G. (2015) Saturated Fatty Acid Inhibits Viral Replication in Chronic Hepatitis B Virus Infection with Nonalcoholic Fatty Liver Disease by Toll-Like Receptor 4-Mediated Innate Immune Response. Hepatitis Monthly, 15, e27909. https://doi.org/10.5812/hepatmon.15(5)2015.27909
|
[22]
|
Zhou, Z., Zeng, C., Nie, L., et al. (2017) The Effects of TLR3, TRIF and TRAF3 SNPs and Interactions with Environmental Factors on Type 2 Diabetes Mellitus and Vascular Complications in a Han Chinese Population. Gene, 626, 41-47. https://doi.org/10.1016/j.gene.2017.05.011
|
[23]
|
Aragonès, G., Colom-Pellicer, M., Aguilar, C., et al. (2020) Cir-culating Microbiota-Derived Metabolites: A Liquid Biopsy. International Journal of Obesity (London), 44, 875-885. https://doi.org/10.1038/s41366-019-0430-0
|
[24]
|
Baumann, A., Nier, A., Hernández-Arriaga, A., et al. (2021) Toll-Like Receptor 1 as a Possible Target in Non-Alcoholic Fatty Liver Disease. Scientific Reports, 11, Article No. 17815. https://doi.org/10.1038/s41598-021-97346-9
|
[25]
|
Zu, L., He, J., Jiang, H., Xu, C., Pu, S. and Xu, G. (2009) Bac-terial Endotoxin Stimulates Adipose Lipolysis via Toll- Like Receptor 4 and Extracellular Signal-Regulated Kinase Path-way. Journal of Biological Chemistry, 284, 5915-5926.
https://doi.org/10.1074/jbc.M807852200
|
[26]
|
Pan, X., Chiwanda Kaminga, A., Liu, A., Wen, S.W., Chen, J. and Luo, J. (2020) Chemokines in Non-Alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis. Frontiers in Immunology, 11, Article No. 1802.
https://doi.org/10.3389/fimmu.2020.01802
|
[27]
|
Carpino, G., Del Ben, M., Pastori, D., et al. (2020) Increased Liver Localization of Lipopolysaccharides in Human and Experimental NAFLD. Hepatology, 72, 470-485. https://doi.org/10.1002/hep.31056
|
[28]
|
Zhang, Z., Xu, X., Tian, W., et al. (2020) ARRB1 Inhibits Non-Alcoholic Steatohepatitis Progression by Promoting GDF15 Maturation. Journal of Hepatology, 72, 976-989. https://doi.org/10.1016/j.jhep.2019.12.004
|
[29]
|
Bertran, L., Jorba-Martin, R., Barrientos-Riosalido, A., et al. (2022) New Insights of OLFM2 and OLFM4 in Gut-Liver Axis and Their Potential Involvement in Nonalcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 23, Article No. 7442. https://doi.org/10.3390/ijms23137442
|
[30]
|
Tsai, H.C., Chang, F.P., Li, T.H., et al. (2019) Elafibranor Inhibits Chronic Kidney Disease Progression in NASH Mice. BioMed Research International, 2019, Article ID: 6740616. https://doi.org/10.1155/2019/6740616
|
[31]
|
Zhang, X., Fan, L., Wu, J., et al. (2019) Macrophage p38α Promotes Nutritional Steatohepatitis through M1 Polarization. Journal of Hepatology, 71, 163-174. https://doi.org/10.1016/j.jhep.2019.03.014
|
[32]
|
Brenner, C., Galluzzi, L., Kepp, O. and Kroemer, G. (2013) De-coding Cell Death Signals in Liver Inflammation. Journal of Hepatology, 59, 583-594. https://doi.org/10.1016/j.jhep.2013.03.033
|
[33]
|
刘新月, 周璐瑾, 马玉, 王文栋, 郝敏, 常晓彤. Toll样受体2和肠道菌群在高脂饮食诱导的胰岛素抵抗中的作用[J]. 现代预防医学, 2022, 49(10): 1881-1886+1891.
|
[34]
|
曹荟哲. 游离脂肪酸致胰岛素抵抗的机制研究[D]: [硕士学位论文]. 兰州: 兰州理工大学, 2017.
|
[35]
|
DiBaise, J.K., Zhang, H., Crowell, M.D., Krajmalnik-Brown, R., Decker, G.A. and Rittmann, B.E. (2008) Gut Microbiota and Its Pos-sible Relationship with Obesity. Mayo Clinic Proceedings, 83, 460-469.
https://doi.org/10.4065/83.4.460
|
[36]
|
Dong, X., Liu, H., Chen, F., Li, D. and Zhao, Y. (2014) MiR-214 Promotes the Alcohol-Induced Oxidative Stress via Down-Regulation of Glutathione Reductase and Cytochrome P450 Oxidore-ductase in Liver Cells. Alcohol: Clinical and Experimental Research, 38, 68-77. https://doi.org/10.1111/acer.12209
|
[37]
|
Edfeldt, K., Swedenborg, J., Hansson, G.K. and Yan, Z.Q. (2002) Expres-sion of Toll-Like Receptors in Human Atherosclerotic Lesions: A Possible Pathway for Plaque Activation. Circulation, 105, 1158-1161.
https://doi.org/10.1161/circ.105.10.1158
|
[38]
|
Hritz, I., Mandrekar, P., Velayudham, A., et al. (2008) The Critical Role of Toll-Like Receptor (TLR) 4 in Alcoholic Liver Disease Is Independent of the Common TLR Adapter MyD88. Hepatology, 48, 1224-1231.
https://doi.org/10.1002/hep.22470
|
[39]
|
Ishibashi, M., Sayers, S., D’Armiento, J.M., Tall, A.R. and Welch, C.L. (2013) TLR3 Deficiency Protects against Collagen Degradation and Medial Destruction in Murine Atherosclerotic Plaques. Atherosclerosis, 229, 52-61.
https://doi.org/10.1016/j.atherosclerosis.2013.03.035
|
[40]
|
Sun, Y., Ishibashi, M., Seimon, T., et al. (2009) Free Cholesterol Accumulation in Macrophage Membranes Activates Toll-Like Receptors and p38 Mitogen-Activated Protein Kinase and Induces Cathepsin K. Circulation Research, 104, 455-465. https://doi.org/10.1161/CIRCRESAHA.108.182568
|
[41]
|
Albillos, A., de Gottardi, A. and Rescigno, M. (2020) The Gut-Liver Axis in Liver Disease: Pathophysiological Basis for Therapy. Journal of Hepatology, 72, 558-577. https://doi.org/10.1016/j.jhep.2019.10.003
|
[42]
|
Bauer, K.C., Littlejohn, P.T., Ayala, V., Creus-Cuadros, A. and Finlay, B.B. (2022) Nonalcoholic Fatty Liver Disease and the Gut-Liver Axis: Exploring an Undernutrition Perspective. Gastroenterology, 162, 1858-1875.e2.
https://doi.org/10.1053/j.gastro.2022.01.058
|
[43]
|
Tripathi, A., Debelius, J., Brenner, D.A., et al. (2018) The Gut-Liver Axis and the Intersection with the Microbiome. Nature Reviews Gastroenterology & Hepatology, 15, 397-411. https://doi.org/10.1038/s41575-018-0011-z
|
[44]
|
Hwang, S., He, Y., Xiang, X., et al. (2020) Interleukin-22 Ame-liorates Neutrophil-Driven Nonalcoholic Steatohepatitis through Multiple Targets. Hepatology, 72, 412-429. https://doi.org/10.1002/hep.31031
|
[45]
|
Qiao, Y., Li, X., Zhang, X., et al. (2019) Hepatocellular iNOS Protects Liver from NASH through Nrf2-Dependent Activation of HO-1. Biochemical and Biophysical Research Communica-tions, 514, 372-378.
https://doi.org/10.1016/j.bbrc.2019.04.144
|
[46]
|
Song, K., Kwon, H., Han, C., et al. (2020) Yes-Associated Protein in Kupffer Cells Enhances the Production of Proinflammatory Cytokines and Promotes the Development of Nonalcoholic Steatohepatitis. Hepatology, 72, 72-87.
https://doi.org/10.1002/hep.30990
|